Posted on

Buy Modafinil (Modiodal Provigil) Online | iModaf

Buy Modafinil (Modiodal Provigil) Online
Modiodal Modafinil buy online at iModaf.com
  • Euphoria
  • Mental stimulation
  • Improved physical performance
  • Increased Wakefulness
  • Increased alertness
  • Stimulation
  • Increased Libido
  • Thought acceleration
  • Focus enhancement
  • Physical euphoria
  • Cognitive euphoria
  • Appetite suppression
  • Memory enhancement
  • Analysis enhancement
  • Increased music appreciation
  • General Cognitive Enhancement
Authentic Modafinil | Lowest Prices | Free Shipping

Modafinil reduces extreme sleepiness due to narcolepsy and other sleep disorders, such as obstructive sleep apnoea. It helps one stay awake during work hours and particularly suitable for work schedules that prevent ‘normal’ sleep habits (shift work sleep disorder). Buy Modafinil (Modiodal Provigil) Online here at iModaf. Authentic Modafinil.

Modafinil does not take the place of getting enough sleep. It is not known how modafinil works to keep one awake and energetic. It is thought to work by affecting certain substances in the brain that control the sleep/wake cycle.

Buy Modafinil (Modiodal Provigil) online here at iModaf.com – Your number one AUTHENTIC modafinil source.

Posted on Leave a comment

Generic Provigil Availability

pseudo modafinil

PROVIGIL (modafinil tablet;oral)

  • Manufacturer: CEPHALON
    Approval date: December 24, 1998
    Strength(s): 100MG [RLD] [AB], 200MG [RLD] [AB]

Has a generic version of Provigil been approved?

A generic version of Provigil has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available – possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Provigil and have been approved by the FDA:

modafinil tablet;oral

  • Manufacturer: ALEMBIC PHARMS LTD
    Approval date: October 18, 2012
    Strength(s): 100MG [AB], 200MG [AB]
  • Manufacturer: APOTEX INC
    Approval date: February 3, 2014
    Strength(s): 100MG [AB], 200MG [AB]
  • Manufacturer: APPCO
    Approval date: August 16, 2017
    Strength(s): 100MG [AB], 200MG [AB]
  • Manufacturer: AUROBINDO PHARMA LTD
    Approval date: September 27, 2012
    Strength(s): 100MG [AB], 200MG [AB]
  • Manufacturer: CADILA
    Approval date: September 14, 2017
    Strength(s): 100MG [AB], 200MG [AB]
  • Manufacturer: MYLAN PHARMS INC
    Approval date: July 16, 2012
    Strength(s): 100MG [AB], 200MG [AB]
  • Manufacturer: ORCHID HLTHCARE
    Approval date: September 26, 2012
    Strength(s): 100MG [AB], 200MG [AB]
  • Manufacturer: WATSON LABS INC
    Approval date: November 1, 2012
    Strength(s): 100MG [AB], 200MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Provigil. These medications may be counterfeit and potentially unsafe.

Posted on Leave a comment

iModaf.com How it all began…

iModaf.com How it all began…

A brief description and history of a company that offered something THAT WAS and still is too good to be true.

Based in Europe iModaf.com sells Modiodal which is identical to Provigil in the United States.  The only difference is the naming of the product. – Buy European Teva Original Brand Name Modafinil Online.  We are a viable, cost-effective alternative to the rest of the sites buying stock from clandestine labs and selling the same cheap shoddy generic products manufactured under questionable circumstances from the world’s most impoverished regions.

The Launch

iModaf launches (unfortunately during the onset of the covid-19 pandemic).  “

The new kid on the block” as one TrustPilot reviewer proclaimed.  He gave us the full whammy in terms of stars.  (To satisfy the curious). 😉

The dark period

Before arriving on the scene, online Modafinil buyers that wanted to purchase modafinil but could not buy the highest grade pharmaceutical product whether it be its off-limits price tag or lack of other means were compelled to either:

1) Pay exorbitant costs for a lab test to test what the pills actually contained.

2) Play Russian roulette with their lives.   Thankfully since iModaf.com arrived on the scene.

Unfortunately, most online buyers did the latter and with the long-term consequences still unknown to us today, it remains to be seen what the science will reveal in several more years! It’s known amongst the community that .any of the so called generics have either been contaminated, underdosed or laced with toxic chemicals. There’s a reason the authentic products that the military, astronauts and fighter pilots use vary tremendously in cost…..


Brace yourself:

Modafinil price from drugs.com
https://www.drugs.com/price-guide/provigil
Modiodal Price
Posted on

Some common sense

iModaf bried company history

Don’t buy junk. Make your health a priority.

A brief description and history of a company that offered something THAT WAS and still is too good to be true.

Based in Europe iModaf.com sells Modiodal which is identical to Provigil in the United States.  The only difference is the naming of the product. – Buy European Teva Original Brand Name Modafinil Online. 

The dark period

Before arriving on the scene, online Modafinil buyers that wanted to purchase modafinil but could not buy the highest grade pharmaceutical product whether it be its off-limits price tag or lack of other means were compelled to either:

1) pay exorbitant prices for a lab test to test what the pills contained.

2) play Russian roulette with their health.   Thankfully iModaf.com arrived on the scene.

Unfortunately, most online buyers did the latter and with the long-term consequences still unknown to us today, it remains to be seen what the science will reveal in several more years! It’s known amongst the community that the so-called generics have caused harm in certain individuals via the ingestion of contaminated pills.

Often batches of the Indian pills are underdosed, contain ephedrine hydrochloride, not Modafinil, and many batches were laced with toxic chemicals and fillers which gives them that chalky texture.

There’s a reason the authentic products that the top entrepreneurs, military, astronauts, and fighter pilots use vary tremendously in cost…..

Brace yourself:


Modafinil price from drugs.com
https://www.drugs.com/price-guide/provigil
Modiodal Price

We are a viable, cost-effective alternative to the rest of the sites buying stock from clandestine labs and selling the same cheap shoddy generic products manufactured under questionable circumstances from the world’s most impoverished regions. This describes what many have attested to by highlighting the discrepancies found as no batch is identical to the previous one.

The Launch

iModaf launches (unfortunately during the onset of the covid-19 pandemic).  “

The new kid on the block” as one TrustPilot reviewer proclaimed.  He gave us the full whammy in terms of stars.  (To satisfy the curious). 😉
Posted on

Modiodal modafinil – Products

iModaf bried company history

Modiodal logo

The days where you had to resort to buying second-grade modafinil from India are finally over.

Performance boosting eugeroic modafinil is the world’s first safe ‘smart pill’

Posted on

Buy modafinil online at iModaf.

Modafinil at iModaf

Buy Modafinil Online | Best Site to Order Provigil Online 2021

Modafinil is a eugeroic that’s commonly used to treat cases of narcolepsy in adults. It’s described as a “wakefulness-promoting agent”, and belongs to the nootropic and psychoanalytic families of medicines.

Those with narcolepsy often struggle with staying awake during the day, no matter how much sleep they’ve had at night. It’s a medical condition that affects around 30,000 people in the UK alone and can be a frustrating and embarrassing thing to live with, and can also cause temporary muscle weakness (called cataplexy).

Modafinil is very effective at reducing the symptoms of narcolepsy, and often improves the quality of life for sufferers. Modafinil isn’t a cure for narcolepsy, but it is an effective treatment that makes the condition easier to live with.

Details

What is Modafinil

Modafinil is a legal medicine that is licenced in most countries around the world for the treatment for narcolepsy in adults. You can buy modafinil in its generic form, or also as the branded version named Provigil in the United States and Modiodal in the European Union. (they are identical).

Despite this, some patients prefer to use cheap generics from India, and vice versa.

Modafinil helps those with narcolepsy to stay awake. It isn’t fully understood how it works yet, but it’s thought to stimulate a part of the brain and affect several neurotransmitters, especially those that are involved with sleep and wakefulness.

However, one theory about modafinil is that it increases the amount of dopamine – a chemical that’s responsible for regulating sleep and wakefulness. Whilst the mechanism of modafinil isn’t completely understood, what we do know is that it significantly reduces feelings of sleepiness and fatigue, meaning that those struggling with narcolepsy can lead a normal life without as many sleep attacks.

How long does modafinil take to kick in

For most people, modafinil only takes around 30 minutes to an hour to start working.

Products page

Posted on

Buy Modafinil Online

modiodal modafinil brand name modafinil online

Buy Modiodal Modafinil

Modafinil is used to treat excessive sleepiness caused by narcolepsy (a condition that causes excessive daytime sleepiness) or shift work sleep disorder. Buy Modiodal Modafinil. Teva European made Modafinil you can trust.

Buy Authentic.

Modafinil is a very effective cognitive enhancer. It also has its use in those working awkward hours (shift work disorder).


Many sites offer Indian generics. iModaf offers quality Modiodal made in Europe. Modiodal is the brand name used in Europe for the American original modafinil product Provigil.

Homepage

Posted on

Modafinil is the world’s first safe ‘smart drug’

modiodal modafinil brand name modafinil online

Performance boosting eugeroic modafinil is the world’s first safe ‘smart pill’

Increasingly taken by healthy people to improve focus before exams, after a comprehensive review researchers say modafinil is safe in the short-term.

Modafinil is the world’s first safe “smart drug”, researchers at Harvard and Oxford universities have said, after performing a comprehensive review of the drug. They concluded that the drug, which is prescribed for narcolepsy but is increasingly taken without prescription by healthy people, can improve decision- making, problem-solving and possibly even make people think more creatively.

While acknowledging that there was limited information available on the effects of long-term use, the reviewers said that the drug appeared safe to take in the short term, with few side effects and no addictive qualities.

Modafinil has become increasingly common in universities across Britain and the US. Prescribed in the UK as Provigil, it was licensed in 2002 for use as a treatment for narcolepsy – a brain disorder that can cause a person to suddenly fall asleep at inappropriate times or to experience chronic pervasive sleepiness and fatigue.

Used without prescription, modafinil is what is known as a smart drug – used primarily by people wanting to improve their focus before an exam. A poll of Nature journal readers suggested that one in five have used drugs to improve focus, with 44% stating modafinil as their drug of choice.

A new review of 24 of the most recent modafinil studies suggests that the drug has many positive effects in healthy people, including enhancing attention, improving learning and memory and increasing something called “fluid intelligence” – essentially our capacity to solve problems and think creatively. One study also showed that modafinil made tasks seem more pleasurable. The longer and more complex the task tested, the more consistently modafinil conferred cognitive benefits, the authors of the review said.

The review points out that negative effects – including one study that showed that people already classed as creative saw a small drop in creativity – were reported in a small number of tasks, but never consistently. It added that the drug exerts positivd effects on mood, and only causes minor side effects such as nausea, headaches and anxiety, although these were also reported by people who took a placebo drug.

Other proposed stimulants, such as Ritalin and Adderall (Amphetamine), prescribed for ADHD, have many negative side effects, said Anna-Katharine Brem, co-author of the review, published today in the journal European Neuropsychopharmacology. “Modafinil seems to be the first ‘smart drug’ that is safe for healthy people.”

She emphasised that although the drug is not thought to be addictive, its long-term effects have not been studied. “It would be difficult to get ethical approval to test the effects of taking this drug in the long term,” she said.

Peter Morgan, at Yale School of Medicine, says there is substantial evidence that other cognitive enhancers, such as caffeine or nicotine, have benefited from short-term use, but that those benefits are erased by long-term use, and are rather replaced by deficiencies in cognitive performance.

The effects of modafinil on the brain are complex and not well understood. One promising theory is that the drug increases blood flow to brain areas serving attention and learning. It might also enhance brain activity in areas thought to act as “conductors”, which manage skills like memory, reasoning and problem-solving.

“Modafinil is the first real example of a smart drug which can genuinely help, for example, with exam preparation,” said Guy Goodwin, president of the European College of Neuropsychopharmacology. “Previous ethical discussion of such agents has tended to assume extravagant effects before it was clear that there were any. If correct, the present update means the ethical debate is real: how should we classify, condone or condemn a drug that improves human performance in the absence of pre-existing cognitive impairment?”

Goodwin points out that drugs are approved to treat illnesses if they are effective and safe. The manufacturers of modafinil will not attempt to extend the licence to exam doping and there would be no precedent for handling such an application if they did, he said.

“That leaves us in uncharted territory.

Brem and her co-author Ruairidh Battleday think that time for debate has come. “For the first time, we have an agent without serious side effects showing the benefits which we haven’t had before.”

“We’re not saying ‘go out and take this drug and your life will be better’,” said Brem. “It is time for a wider debate on how to integrate cognitive enhancement into our lives. We need to explore the ethics, and scientist, politicians and the public need to be involved.”

Content retrieved from https://www.theguardian.com/science/2015/aug/20/narcolepsy-medication-modafinil-worlds-first-safe-smart-drug.


Modiodal modafinil – Products
The action of modafinil – increased motivation via the dopamine transporter inhibition and D1 receptors?

Posted on

The action of modafinil – increased motivation via the dopamine transporter inhibition and D1 receptors?

action of modafinil

Action of modafinil on increased motivation (study).

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2849918/

The mean (SD) reductions in [11C]raclopride and [11C]cocaine BPND after modafinil were similar to those reported for a 20-mg oral dose of methylphenidate in normal volunteers, which corresponded to about 5% (6%) for raclopride28 and to about 54% (5%) for [11C]cocaine.27 This indicates that modafinil at therapeutic doses produces elevations in brain dopamine through blockade of dopamine transporters, which are similar to those produced by therapeutic doses of methylphenidate. Even though modafinil’s affinity for dopamine transporters is low relative to methylphenidate (6.390 μM vs 0.025 μM14), the therapeutic doses are much higher for modafinil (200 mg) than for methylphenidate (20 mg).

Drug Effects

Two doses of modafinil (200 mg and 400 mg) were evaluated, but neither the plasma modafinil concentrations nor the dopamine transporter blockade or dopamine changes differed between the 2 doses, which may reflect the relatively small sample of the study. The lack of a dose effect is also confounded by the large participant variability in modafinil’s plasma concentrations (particularly for 1 participant in the 400-mg dose group) (Figure 2), which predicted the level of dopamine transporter occupancy (Figure 3).

The variability in plasma modafinil concentration is likely to reflect variability in metabolism of modafinil. Neither modafinil’s plasma concentration nor the level of dopamine transporter occupancy correlated with the dopamine changes. We had reported a similar finding with methylphenidate in which a correlation was found between plasma concentration and dopamine transporter occupancy, but neither plasma concentration nor dopamine transporter occupancy correlated with dopamine changes.32 This reflects that although plasma (and presumably brain) modafinil levels proportionally compete with [11C]cocaine for binding to the dopamine transporters, decreases in [11C]raclopride binding are a function of changes in extracellular dopamine, which are determined not only by dopamine transporter blockade but also by dopamine cell firing. For the same level of dopamine transporter blockade, dopamine changes will be greater when the activity of dopamine cells is high than when it is low.

Stimulant medications act as wake-promoting agents by increasing dopamine (as well as norepinephrine) in brain.6 Modafinil was developed with an expectation that a medication could have a nondopaminergic target for its wake-promoting effects. However, the current findings in humans, along with preclinical studies,9,10 documenting the indispensable role of dopamine in the wake-promoting effects of modafinil, support modafinil’s dopamine-enhancing effects as a mechanism for its therapeutic actions.

The dopamine-enhancing effects of modafinil in the nucleus accumbens may help explain reports of its abuse, since this pharmacological effect is considered crucial for drug reinforcement.33 Indeed, modafinil was shown to be self-administered in monkeys previously trained to self-administer cocaine,34 and in humans modafinil can act as a reinforcer under conditions of behavioral demand.35 However, modafinil is much less potent as a reinforcer than stimulant drugs, and reports of modafinil abuse are rare and much less frequent than those for stimulant drugs.36 Nonetheless, considering the broadening use of modafinil and the results in this study showing that it increases dopamine in the nucleus accumbens at therapeutic doses, its potential for abuse should not be disregarded.

In this study, modafinil’s binding to dopamine transporters overlapped with the binding site of cocaine. This could account for the findings that modafinil interfered with the behavioral effects of cocaine.37 Indeed pilot studies have reported some beneficial effects of modafinil in the treatment of cocaine addiction.38

Study Limitations

The [11C]raclopride method does not allow the exclusion of the possibility that decreases reflect down-regulation of D2/D3 receptors and changes in affinity39 rather than dopamine increases. Since microdialysis studies9,1113 have shown that modafinil increases dopamine in striatum (including nucleus accumbens), this suggests that the findings in this study reflect dopamine increases. The small sample size of the study did not provide sufficient statistical power to detect dose effects. Only healthy young men were tested, which may limit generalizability to other populations. This study did not use a complete placebo design but rather used a placebo to compare the effects of modafinil on each radiotracer, which required that the placebo be given first and the modafinil second, so the possibility of an order effect cannot be ruled out. The order of modafinil doses tested was not randomized; instead the first 5 participants were tested with 200 mg and the subsequent 5 with 400 mg. However, it is unlikely that this affected the results obtained. This study did not measure a clinical outcome, so further studies are necessary to assess this.Go to:

CONCLUSION

In this pilot study, modafinil acutely increased dopamine levels and blocked dopamine transporters in the human brain. Because drugs that increase dopamine have the potential for abuse, and considering the increasing use of modafinil for multiple purposes, these results suggest that risk for addiction in vulnerable persons merits heightened awareness.Go to:

Acknowledgments

Financial Disclosures: None reported.

Funding/Support: This research was carried out at Brookhaven National Laboratory under contract DE-AC02-98CH10886 with the US Department of Energy with infrastructure support from its Office of Biological and Environmental Research. Support was also provided by grant K05DA020001 (J.S.F.) from the National Institutes of Health, the National Institute on Alcohol Abuse and Alcoholism Intramural research program, grant F32EB997320 (J.M.H.) from the National Institute of Biomedical Imaging and Bioengineering, and grant MO1RR10710 from the General Research Clinical Centers. A Goldhaber distinguished fellowship provided support for Dr Hooker.

Role of the Sponsor: The funding agencies had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.Go to:

Footnotes

Author Contributions: Dr Volkow had full access to all of the data in the study and takes full responsibility for the integrity of the data and the accuracy of the data analysis. Drs Volkow and Fowler contributed equally to this work.

Study concept and design: Volkow, Fowler, Wang.

Acquisition of data: Telang, Wang, Jayne, Hubbard, Carter, Warner, King, Shea, Xu, Muench, Apelskog-Torres.

Analysis and interpretation of data: Volkow, Fowler, Logan, Alexoff, Zhu, Hooker, Wong.

Drafting of the manuscript: Volkow, Fowler, Alexoff, Telang, Wang, Jayne, Hooker, Wong, Hubbard, Carter, Warner, King, Shea, Xu, Muench, Apelskog-Torres.

Critical revision of the manuscript for important intellectual content: Volkow, Fowler, Logan, Zhu.

Statistical analysis: Zhu.

Obtained funding: Volkow, Fowler.

Administrative, technical, or material support: Telang, Wang, Jayne, Hubbard, Carter, Apelskog-Torres.

Study supervision: Volkow, Fowler, Wang.

Previous Presentation: Presented at the 55th Annual Society of Nuclear Medicine meeting; June 16, 2008; New Orleans, Louisiana.

Additional Contributions: David Schlyer, PhD, and Michael Schueller, PhD, Brookhaven National Laboratory, assisted with cyclotron operations. Joan Terry, and Hai-Dee Lee, MS, Brookhaven National Laboratory, assisted with clinical research center operations. Nikhil Pujari, BS, State University of New York at Stony Brook, helped with the image analysis, and Linda Thomas, BS, National Institutes of Health, provided editorial assistance. None received compensation outside of their salaries. We thank the individuals who volunteered for these studies, who each received a volunteer fee.Go to:

References

1. Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology. 2008;33(7):1477–1502. [PubMed] [Google Scholar]2. Enhancing not cheating. Nature. 2007;450 (7168):320. [PubMed] [Google Scholar]3. Provigil (modafinil) Physicians’ Desk Reference. 60. Montvale, NJ: Thompson PDR; 2006. pp. 1002–1007. [Google Scholar]4. Kruszewski SP, Klotz SG. Modafinil: mischaracterization. J Clin Psychiatry. 2007;68(6):970–971. [PubMed] [Google Scholar]5. Kruszewski SP. Euphorigenic and abusive properties of modafinil. Am J Psychiatry. 2006;163(3):549. [PubMed] [Google Scholar]6. Greenhill LL. The science of stimulant abuse. Pediatr Ann. 2006;35(8):552–556. [PubMed] [Google Scholar]7. Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate- and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci U S A. 1996;93(24):14128–14133. [PMC free article] [PubMed] [Google Scholar]8. Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci. 2000;20(22):8620–8628. [PMC free article] [PubMed] [Google Scholar]9. Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. Dopaminergic role in stimulant-induced wakefulness. J Neurosci. 2001;21(5):1787–1794. [PMC free article] [PubMed] [Google Scholar]10. Qu WM, Huang ZL, Xu XH, Matsumoto N, Urade Y. Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil. J Neurosci. 2008;28(34):8462–8469. [PMC free article] [PubMed] [Google Scholar]11. Ferraro L, Antonelli T, O’Connor WT, Tanganelli S, Rambert FA, Fuxe K. Modafinil: an antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers. Biol Psychiatry. 1997;42(12):1181–1183. [PubMed] [Google Scholar]12. de Saint Hilaire Z, Orosco M, Rouch C, Blanc G, Nicolaidis S. Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats. Neuroreport. 2001;12(16):3533–3537. [PubMed] [Google Scholar]13. Murillo-Rodríguez E, Haro R, Palomero-Rivero M, Millán-Aldaco D, Drucker-Colín R. Modafinil enhances extracellular levels of dopamine in the nucleus accumbens and increases wakefulness in rats. Behav Brain Res. 2007;176(2):353–357. [PubMed] [Google Scholar]14. Madras BK, Xie Z, Lin Z, et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther. 2006;319 (2):561–569. [PubMed] [Google Scholar]15. Minzenberg MJ, Watrous AJ, Yoon JH, Ursu S, Carter CS. Modafinil shifts human locus coeruleus to low tonic, high-phasic activity during functional MRI. Science. 2008;322(5908):1700–1702. [PubMed] [Google Scholar]16. Volkow N, Li TK. The neuroscience of addiction. Nat Neurosci. 2005;8(11):1429–1430. [PubMed] [Google Scholar]17. Biederman J, Swanson JM, Wigal SB, Boellner SW, Earl CQ, Lopez FA. Modafinil ADHD Study Group. A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study. J Clin Psychiatry. 2006;67(5):727–735. [PubMed] [Google Scholar]18. Volkow ND, Wang GJ, Fowler JS, et al. Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse. 1994;16(4):255–262. [PubMed] [Google Scholar]19. Fowler JS, Volkow ND, Wolf AP, et al. Mapping cocaine binding sites in human and baboon brain in vivo. Synapse. 1989;4(4):371–377. [PubMed] [Google Scholar]20. Ehrin E, Gawell L, Hogberg T, Depaulis T, Strom P. Synthesis of [methoxy-3H]- and [methoxy-11C]-labelled raclopride: specific dopamine-D2 receptor ligands. J Labelled Comp Radiopharm. 1987;24 (8):931–940. [Google Scholar]21. Alexoff DL, Shea C, Fowler JS, et al. Plasma input function determination for PET using a commercial laboratory robot. Nucl Med Biol. 1995;22(7):893–904. [PubMed] [Google Scholar]22. Wang GJ, Volkow ND, Hitzemann RJ, et al. Behavioral and cardiovascular effects of intravenous methylphenidate in normal subjects and cocaine abusers. Eur Addict Res. 1997;3:49–54. [Google Scholar]23. MacNair DM, Lorr M, Droppelman LF. EDITS Manual for the Profile of Mood States. San Diego, CA: Educational and Industrial Testing Service; 1971. [Google Scholar]24. Logan J, Fowler JS, Volkow ND, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(−)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10(5):740–747. [PubMed] [Google Scholar]25. Logan J, Volkow ND, Fowler SJ, et al. Effects of blood flow on [11C]raclopride binding in the brain: model simulations and kinetic analysis of PET data. J Cereb Blood Flow Metab. 1994;14(6):995–1010. [PubMed] [Google Scholar]26. SPM: Statistical Parametric Mapping. [Accessed February 18, 2009]. http://www.fil.ion.ucl.ac.uk/spm/27. Volkow ND, Wang GJ, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry. 1998;155(10):1325–1331. [PubMed] [Google Scholar]28. Volkow ND, Wang GJ, Fowler JS, et al. “Nonhedonic” food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect. Synapse. 2002;44(3):175–180. [PubMed] [Google Scholar]29. SAS Institute Inc. SAS/STAT 9.2 user’s guide. [Accessed February 18, 2009]. http://support.sas.com/documentation/onlinedoc/stat/index.html.30. Crone C. The permeability of capillaries in various organs as determined by the use of the “indicator diffusion” method. Acta Physiol Scand. 1963;58:292–305. [PubMed] [Google Scholar]31. Joo EY, Tae WS, Jung KY, Hong SB. Cerebral blood flow changes in man by wake-promoting drug, modafinil: a randomized double blind study. J Sleep Res. 2008;17(1):82–88. [PubMed] [Google Scholar]32. Volkow ND, Wang GJ, Fowler JS, et al. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse. 2002;43(3):181–187. [PubMed] [Google Scholar]33. Myrick H, Malcolm R, Taylor B, LaRowe S. Modafinil: preclinical, clinical and post-marketing surveillance: a review of abuse liability issues. Ann Clin Psychiatry. 2004;16(2):101–109. [PubMed] [Google Scholar]34. Gold LH, Balster RL. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology (Berl) 1996;126(4):286–292. [PubMed] [Google Scholar]35. Stoops WW, Lile JA, Fillmore MT, Glaser PEA, Rush CR. Reinforcing effects of modafinil: influence of dose and behavioral demands following drug administration. Psychopharmacology (Berl) 2005;182(1):186–193. [PubMed] [Google Scholar]36. Jasinski DR, Kovacevic-Ristanovic R. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin Neuropharmacol. 2000;23(3):149–156. [PubMed] [Google Scholar]37. Hart CL, Haney M, Vosburg SK, Rubin E, Foltin RW. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology. 2008;33(4):761–768. [PubMed] [Google Scholar]38. Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O’Brien CP. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology. 2005;30(1):205–211. [PubMed] [Google Scholar]39. Gjedde A, Wong DF, Rosa-Neto P, Cumming P. Mapping neuroreceptors at work: on the definition and interpretation of binding potentials after 20 years of progress. Int Rev Neurobiol. 2005;63:1–20. [PubMed] [Google Scholar]